Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Radiation Oncology
With the more recent validation studies, have you integrated the use of DCISion RT into your practice?
What patients, if any, do you use DCISion RT in consideration of management?
Related Questions
Given the new ASCO guidelines on SNB in early stage breast cancer, how does the omission of SNB in patients aged 50-70 impact your adjuvant radiation recommendations?
Would you recommend PMRT for multifocal IDC with extensive LVI and 1 SLN with ITCs?
Do you recommend adjuvant RT to patients with non-ATM genetic mutations (e.g. BRCA, NF) who elect to have lumpectomy and are otherwise PRIME II/CALGB candidates for RT omission (i.e. low risk disease characteristics: strongly ER+, <1cm, grade 1-2, no LVI, widely negative margins, and committed to endocrine therapy)?
Do you hold endocrine therapy during adjuvant breast radiotherapy?
If a patient has multiple PET-avid level 3, supraclavicular, or IMN nodes that are small and would have been considered negative by size criteria with traditional imaging, that are no longer positive on PET after chemotherapy, would you try to boost these nodes?
What are your top takeaways in Breast Cancer from ESMO 2024?
Do you recommend self-breast exams to your patients with history of breast cancer in addition to imaging surveillance?
How are you clinically incorporating the data presented from RT Charm at ASTRO 2024?
Does the presence of LCIS on pathology in a patient with IDC impact your decision to offer APBI?
How would you approach an isolated supraclavicular nodal recurrence involving the skin in a patient who has received standard chest wall and nodal radiation therapy?